NCT06612047 Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer
| NCT ID | NCT06612047 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anhui Provincial Hospital |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-10-08 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-10-08 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to compare 5.0T and 3.0T biparametric magnetic resonance imaging in the diagnosis of prostate cancer. The main aims of this study are: * Compare the diagnostic efficacy of 5.0TbpMRI and 3.0TbpMRI for prostate cancer. Preliminarily evaluate the value of 5.0TbpMRI in diagnosing prostate cancer. * Compare and analyze the accuracy of 5.0TbpMRI and 3.0TbpMRI in determining the T stage of prostate cancer. Preliminary evaluation of the value of 5.0TbpMRI in determining the tumor stage of prostate cancer. The data of participants was collected prospectively.
Eligibility Criteria
Inclusion Criteria: 1. The patient has at least one indication for prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) ); 2. The primary prostate cancer has no other cancer history; 3. The 3.0TbpMRI examination was completed, and the images were clear and accessible; 4. The 5.0TbpMRI examination was further completed, and the images were clear and accessible; 5. The patient fully understands the relevant content of the study and voluntarily signs the informed consent. Exclusion Criteria: 1. The patient has contraindications to MRI examination, such as metal plates and heart stents in the body; 2. The patient does not have an indication for prostate biopsy or refuses biopsy; 3. The patient has contraindications to prostate biopsy; 4. 3.0T MRI considers that the patient has multiple lymph node or bone metastases; 5. The patient has undergone other prostatic surgery in the past; 6. The patient is unable to cooperate, has communication barriers, or refuses to sign the informed consent form.
Contact & Investigator
Jun Xiao, M.D.
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital of USTC
Frequently Asked Questions
Who can join the NCT06612047 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06612047 currently recruiting?
Yes, NCT06612047 is actively recruiting participants. Contact the research team at wcmurologist@mail.ustc.edu.cn for enrollment information.
Where is the NCT06612047 trial being conducted?
This trial is being conducted at Hefei, China.
Who is sponsoring the NCT06612047 clinical trial?
NCT06612047 is sponsored by Anhui Provincial Hospital. The principal investigator is Jun Xiao, M.D. at The First Affiliated Hospital of USTC. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.